Our science
We have 30 years’ experience in translating research into new drugs and diagnostics.
Our capabilities and expertise ensure seamless progress for your research, with a strong commitment to preserving your IP. We also offer tailored strategic advice and can connect you with commercial and not-for-profit partners and patient groups.
Our scientific focus
Antibody development
Access to our advanced antibody technologies, support from our experienced scientists, and over 30 years of antibody expertise.
Small molecule drug discovery
Access our state-of-the-art research facilities, gain support from our highly experienced scientists, and leverage our expertise.
Clinical trial support
We can help you progress healthcare innovations through clinical trials and into clinical use.
Diagnostics development
We support all stages of diagnostics development, from assay design through to clinical validation
Supporting functions and technologies
We develop and provide technologies and functions that support innovative science.
Data science
We design new molecules, analyse complex datasets, build streamlined workflows, implement machine learning into clinical pathways, and more.
Induced pluripotent stem cell (iPSC) technology
Our gold-standard iPSC models for neurodegeneration are essential for effective mode of action (MOA), target validation and drug discovery projects.
Microbiology
Our established facilities and technologies can support the study of mode of action (MOA), antibiotic resistance and drug screening.
Other ways we can support your science
We partner with academics, early-stage biotechs, charities, healthcare professionals and industry.
Funding
Early ventures investment
IP protection and
tech transfer
Some of our partnerships
-
Case study: The first unconjugated antibody against TROP-2, humanized for KisoJi Biotechnology
Working with KisoJi Biotechnology, we’ve humanized a first-in-class unconjugated antibody to target TROP-2, a highly promising cancer cell target. This is the first unconjugated…
-
Funding: LifeArc-CSO fund for Scottish translational researchers
Funding: LifeArc-CSO fund for Scottish translational researchers In association with the Chief Scientist Office (CSO) for the Scottish Government, we support projects led by…
-
Case study: The first unconjugated antibody against TROP-2, humanized for KisoJi Biotechnology
Working with KisoJi Biotechnology, we’ve humanized a first-in-class unconjugated antibody to target TROP-2, a highly promising cancer cell target. This is the first unconjugated…
-
Funding: LifeArc-CSO fund for Scottish translational researchers
Funding: LifeArc-CSO fund for Scottish translational researchers In association with the Chief Scientist Office (CSO) for the Scottish Government, we support projects led by…
Latest news
-
LifeArc appoints new General Counsel and Company Secretary and Chief Communications Officer
-
LifeArc supports research to develop a quick, affordable blood test for the early detection of dementia
-
LifeArc joins transatlantic collaboration to develop a treatment for Crimean-Congo Hemorrhagic Fever